CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates

DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows:

Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires. 100 mm is defined as the worst possible discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS score was numerically lower, but not significantly different for BIOD-250 compared to Humalog ® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and Humalog ®, respectively; p=NS). The VAS score for BIOD-238 was significantly higher than that associated with Humalog ® (mean VAS score of 24.2 mm, p=0.029 vs. Humalog ®).

BIOD-G
CONTACT: Seth D. Lewis, +1-646-378-2952

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX